🇺🇸 FDA

Intelligence · Patent portfolio

CORCEPT THERAPEUTICS Patents

Full USPTO pharma patent portfolio for CORCEPT THERAPEUTICS — grant dates, expiration, and drug cross-links.

Patents
120
Expiring ≤24m
3

Quick answer

CORCEPT THERAPEUTICS has 120 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 3 expire within 24 months — use filters for patent-cliff planning.

Page 2 of 3

  1. US 11173165

    Optimizing mifepristone levels for Cushing's patients

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11103514

    Treatment of muscular dystrophy

    Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11073523

    Method for differentially diagnosing ACTH-dependent Cushing's syndrome

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11058670

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11045482

    Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors

    Expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10980797

    Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10973813

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10946005

    Methods for shrinking pituitary tumors

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10898478

    Glucocorticoid receptor modulators to treat cervical cancer

    Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10881660

    Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

    Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10842800

    Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10842801

    Optimizing mifepristone absorption

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10828280

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10787449

    Octahydro fused azadecalin glucocorticoid receptor modulators

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10780097

    Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10660904

    Optimizing mifepristone levels for cushing's patients

    Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10646474

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10610534

    Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10604807

    Methods for diagnosing and assessing treatment for Cushing's syndrome

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10568880

    Glucocorticoid receptor modulators to treat cervical cancer

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10500216

    Optimizing mifepristone absorption

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10495650

    Method for differentially diagnosing ACTH-dependent Cushing's syndrome

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10456392

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10449178

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10413540

    Glucocorticoid receptor modulators to treat cervical cancer

    Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10323034

    Octahydro fused azadecalin glucocorticoid receptor modulators

    Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10314850

    Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10238659

    Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10231983

    Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10213414

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10195214

    Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

    Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10166243

    Optimizing mifepristone levels for cushing'S patients

    Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10166242

    Optimizing mifepristone levels for Cushing's patients

    Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10151763

    Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome

    Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10117852

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10047082

    Octahydro fused azadecalin glucocorticoid receptor modulators

    Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10006924

    Method for differentially diagnosing ACTH-dependent cushing's syndrome

    Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9977875

    Systems and methods of managing treatment of a chronic condition by symptom tracking

    Expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9956216

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9943505

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Expires Mon Apr 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9943526

    Optimizing mifepristone levels for cushing's patients

    Expires Mon Apr 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9829495

    Method for differentially diagnosing ACTH-dependent Cushing's syndrome

    Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9707223

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9321736

    Pyrimidine cyclohexyl glucocorticoid receptor modulators

    Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9273047

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8921348

    Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists

    Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8906917

    Pyrimidine cyclohexyl glucocorticoid receptor modulators

    Expires Mon Dec 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8889867

    Solid forms and process for preparing

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does CORCEPT THERAPEUTICS have?

120 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do CORCEPT THERAPEUTICS patents expire?

3 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.